{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:35:22Z","timestamp":1794494122700,"version":"4.9.1"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015545","name":"Seerave Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["RHUS-0017"],"award-info":[{"award-number":["RHUS-0017"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["INCA_ 16698"],"award-info":[{"award-number":["INCA_ 16698"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["964590"],"award-info":[{"award-number":["964590"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.critrevonc.2025.104767","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T11:30:47Z","timestamp":1747999847000},"page":"104767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["The interplay between gut microbiota, antibiotics, and immune checkpoint inhibitors in patients with cancer: A narrative review with biological and clinical aspects"],"prefix":"10.1016","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7612-0944","authenticated-orcid":false,"given":"Demi","family":"Wekking","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Alves Costa","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Visc\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerina","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Maccioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Loddo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Willard-Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Solinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104767_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107347","article-title":"Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer","volume":"184","author":"Alkan \u015een","year":"2023","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104767_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.immuni.2019.06.002","article-title":"Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8","volume":"51","author":"Bachem","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104767_bib3","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"issue":"6369","key":"10.1016\/j.critrevonc.2025.104767_bib4","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1126\/science.aal5240","article-title":"Analysis of","volume":"358","author":"Bullman","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41392-023-01693-0","article-title":"Intratumoural microbiota: a new frontier in cancer development and therapy","volume":"9","author":"Cao","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104767_bib6","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib7","doi-asserted-by":"crossref","first-page":"1980348","DOI":"10.1080\/19490976.2021.1980348","article-title":"Two ST11","volume":"13","author":"Chiang","year":"2021","journal-title":"Gut Microbes"},{"issue":"81","key":"10.1016\/j.critrevonc.2025.104767_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo2003","article-title":"Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity","volume":"8","author":"Choi","year":"2023","journal-title":"Sci. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104767_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030501","article-title":"The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: the case of cancer","volume":"20","author":"Cianci","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib10","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1038\/s41467-020-16079-x","article-title":"Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer","volume":"11","author":"Coutzac","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ijc.33415","article-title":"Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?","volume":"149","author":"De Silva","year":"2021","journal-title":"Int J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104767_bib12","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104767_bib13","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1158\/2159-8290.CD-21-0236","article-title":"Microbiota-centered interventions: the next breakthrough in immuno-oncology?","volume":"11","author":"Derosa","year":"2021","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104767_bib14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eururo.2020.04.044","article-title":"Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients","volume":"78","author":"Derosa","year":"2020","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104767_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","article-title":"Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer","volume":"28","author":"Derosa","year":"2022","journal-title":"Nat. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104767_bib16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","article-title":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","volume":"28","author":"Dizman","year":"2022","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104767_bib17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.intimp.2005.01.007","article-title":"Effects of a short-course of amoxicillin\/clavulanic acid on systemic and mucosal immunity in healthy adult humans","volume":"5","author":"Dufour","year":"2005","journal-title":"Int Immunopharmacol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104767_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1568812","article-title":"Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors","volume":"8","author":"Elkrief","year":"2019","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41698-024-00630-w","article-title":"Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy","volume":"8","author":"Elkrief","year":"2024","journal-title":"NPJ Precis Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104767_bib20","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.22.00074","article-title":"Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: a population-based study","volume":"41","author":"Eng","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104767_bib21","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.eururo.2017.02.010","article-title":"CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104767_bib22","article-title":"Antibiotic use reduces the efficacy of immune checkpoint inhibitors in patients with urothelial carcinoma: a systematic review and meta-analysis","author":"Febriyanto","year":"2023","journal-title":"Urol. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104767_bib23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41568-022-00513-x","article-title":"Targeting the gut microbiota for cancer therapy","volume":"22","author":"Fernandes","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104767_bib24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1159\/000519108","article-title":"Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma","volume":"10","author":"Fessas","year":"2021","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s40425-019-0574-4","article-title":"Exploring the emerging role of the microbiome in cancer immunotherapy","volume":"7","author":"Fessler","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"6649","key":"10.1016\/j.critrevonc.2025.104767_bib26","doi-asserted-by":"crossref","first-page":"eabo2296","DOI":"10.1126\/science.abo2296","article-title":"A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers","volume":"380","author":"Fidelle","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.104767_bib27","first-page":"1543","article-title":"Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances","volume":"6","author":"Francino","year":"2015","journal-title":"Front Microbiol"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104767_bib28","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.neo.2017.08.004","article-title":"Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients","volume":"19","author":"Frankel","year":"2017","journal-title":"Neoplasia"},{"issue":"7937","key":"10.1016\/j.critrevonc.2025.104767_bib29","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41586-022-05435-0","article-title":"Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer","volume":"611","author":"Galeano Ni\u00f1o","year":"2022","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104767_bib30","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.1021\/acsnano.2c11305","article-title":"Synergistic target of intratumoral microbiome and tumor by metronidazole-fluorouridine nanoparticles","volume":"17","author":"Gao","year":"2023","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41392-021-00795-x","article-title":"Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer","volume":"6","author":"Gao","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2025.104767_bib32","doi-asserted-by":"crossref","unstructured":"Glitza, I.C., Seo, Y.D., Spencer, C.N., Wortman, J.R., Burton, E.M., Alayli, F.A., Loo, C.P., Gautam, S., Damania, A., Densmore, J., Fairchild, J., Cabanski, C.R., Wong, M.C., Peterson, C.B., Weiner, B., Hicks, N., Auni\u0146\u0161, J.G., McChalicher, C., Walsh, E., Tetzlaff, M.T., Hamid, O., Ott, P.A., Boland, G.M., Sullivan, R.J., Grossmann, K.F., Ajami, N.J., LaVallee, T., Henn, M.R., Tawbi, H.A. & Wargo, J.A. (2024) Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity. Cancer Discov, OF1-OF15.","DOI":"10.1158\/2159-8290.26134593"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104767_bib33","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","article-title":"The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy","volume":"33","author":"Gopalakrishnan","year":"2018","journal-title":"Cancer Cell"},{"issue":"6371","key":"10.1016\/j.critrevonc.2025.104767_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.104767_bib35","doi-asserted-by":"crossref","first-page":"1185163","DOI":"10.3389\/fonc.2023.1185163","article-title":"Could the tumor-associated microbiota be the new multi-faceted player in the tumor microenvironment?","volume":"13","author":"Goubet","year":"2023","journal-title":"Front Oncol."},{"issue":"6558","key":"10.1016\/j.critrevonc.2025.104767_bib36","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1126\/science.abc9113","article-title":"peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy","volume":"373","author":"Griffin","year":"2021","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104767_bib37","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.immuni.2015.01.010","article-title":"Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack","volume":"42","author":"Gur","year":"2015","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104767_bib38","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.21873\/anticanres.15312","article-title":"Antibiotic usage reduced overall survival by over 70% in non-small cell lung cancer patients on Anti-PD-1 immunotherapy","volume":"41","author":"Hamada","year":"2021","journal-title":"Anticancer Res"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104767_bib39","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41551-021-00749-2","article-title":"Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel","volume":"5","author":"Han","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s44276-023-00008-8","article-title":"Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle","volume":"1","author":"Hes","year":"2023","journal-title":"BJC reports"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104767_bib41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2020.06.061","article-title":"Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab","volume":"78","author":"Hopkins","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104767_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8281718","article-title":"Oleanolic acid induces autophagy and apoptosis via the AMPK-mTOR signaling pathway in colon cancer","volume":"2021","author":"Hu","year":"2021","journal-title":"J. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104767_bib43","first-page":"781","article-title":"Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe","volume":"31","author":"Jiang","year":"2023"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104767_bib44","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","article-title":"The Diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients With NSCLC","volume":"14","author":"Jin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104767_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104834","article-title":"The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors","volume":"97","author":"Joachim","year":"2023","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104767_bib46","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/s41416-022-01887-3","article-title":"Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer","volume":"127","author":"Kamat","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104767_bib47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/COC.0000000000000813","article-title":"Impact of use of antibiotics on response to immune checkpoint inhibitors and tumor microenvironment","volume":"44","author":"Khan","year":"2021","journal-title":"Am. J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104767_bib48","article-title":"Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response","volume":"4","author":"Kim","year":"2023","journal-title":"Cell Rep. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104767_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000803","article-title":"Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types","volume":"5","author":"Kulkarni","year":"2020","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104767_bib50","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.euo.2019.09.001","article-title":"Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma","volume":"3","author":"Lalani","year":"2020","journal-title":"Eur. Urol. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104767_bib51","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1016\/j.cell.2021.09.019","article-title":"Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment","volume":"184","author":"Lam","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104767_bib52","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","article-title":"Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma","volume":"28","author":"Lee","year":"2022","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104767_bib53","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41564-020-00831-6","article-title":"Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice","volume":"6","author":"Lee","year":"2021","journal-title":"Nat. Microbiol"},{"issue":"37","key":"10.1016\/j.critrevonc.2025.104767_bib54","article-title":"Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: a Chinese population-based study","volume":"99","author":"Li","year":"2020","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.critrevonc.2025.104767_bib55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cytogfr.2023.06.005","article-title":"Exosomes: another intercellular lipometabolic communication mediators in digestive system neoplasms?","volume":"73","author":"Li","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.critrevonc.2025.104767_bib56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2019.01.015","article-title":"Gut microbiome and cancer immunotherapy","volume":"447","author":"Li","year":"2019","journal-title":"Cancer Lett."},{"issue":"48","key":"10.1016\/j.critrevonc.2025.104767_bib57","doi-asserted-by":"crossref","first-page":"26296","DOI":"10.1021\/jacs.3c09472","article-title":"Transforming intratumor bacteria into immunopotentiators to reverse cold tumors for enhanced immuno-chemodynamic therapy of triple-negative breast cancer","volume":"145","author":"Liu","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104767_bib58","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/s41564-019-0541-3","article-title":"Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity","volume":"4","author":"Long","year":"2019","journal-title":"Nat. Microbiol"},{"key":"10.1016\/j.critrevonc.2025.104767_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1065004","article-title":"The negative effect of antibiotics on RCC patients with immunotherapy: a systematic review and meta-analysis","volume":"13","author":"Luo","year":"2022","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104767_bib60","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jtho.2020.03.002","article-title":"NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis","volume":"15","author":"Lurienne","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib61","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1038\/s41467-021-24331-1","article-title":"Microbial short-chain fatty acids modulate CD8","volume":"12","author":"Luu","year":"2021","journal-title":"Nat. Commun."},{"issue":"6510","key":"10.1016\/j.critrevonc.2025.104767_bib62","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104767_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003334","article-title":"Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers","volume":"9","author":"Mao","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"6371","key":"10.1016\/j.critrevonc.2025.104767_bib64","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"issue":"75","key":"10.1016\/j.critrevonc.2025.104767_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn0704","article-title":"The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer","volume":"7","author":"Mirji","year":"2022","journal-title":"Sci. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104767_bib66","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jnci\/djaa057","article-title":"Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy","volume":"113","author":"Mohiuddin","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104767_bib67","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104767_bib68","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210108","article-title":"Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10","volume":"218","author":"Mowat","year":"2021","journal-title":"J. Exp. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104767_bib69","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.230014","article-title":"Short chain fatty acids: key regulators of the local and systemic immune response in inflammatory diseases and infections","volume":"13","author":"Ney","year":"2023","journal-title":"Open Biol."},{"key":"10.1016\/j.critrevonc.2025.104767_bib70","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2021.02.040","article-title":"The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression","volume":"149","author":"Ochi","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib71","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1038\/s41467-020-16967-2","article-title":"Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression","volume":"11","author":"Parhi","year":"2020","journal-title":"Nat. Commun."},{"issue":"7960","key":"10.1016\/j.critrevonc.2025.104767_bib72","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-023-06026-3","article-title":"Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance","volume":"617","author":"Park","year":"2023","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104767_bib73","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1172\/JCI32205","article-title":"Microbial translocation augments the function of adoptively transferred self\/tumor-specific CD8+\u2009T cells via TLR4 signaling","volume":"117","author":"Paulos","year":"2007","journal-title":"J. Clin. Invest"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104767_bib74","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.eururo.2021.05.018","article-title":"Is there a detrimental effect of antibiotic therapy in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab?","volume":"80","author":"Pederzoli","year":"2021","journal-title":"Eur. Urol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104767_bib75","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1158\/2326-6066.CIR-19-1014","article-title":"The gut microbiome is associated with clinical response to anti-PD-1\/PD-L1 immunotherapy in gastrointestinal cancer","volume":"8","author":"Peng","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104767_bib76","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.immuni.2022.03.008","article-title":"Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer","volume":"55","author":"Peuker","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104767_bib77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/cancers15082342","article-title":"Antibiotics significantly decrease the survival of head and neck carcinoma patients with immunotherapy: a real-world analysis of more than 3000 cases","volume":"15","author":"Preissner","year":"2023","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104767_bib78","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6371","key":"10.1016\/j.critrevonc.2025.104767_bib79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104767_bib80","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib81","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00280-019-03993-1","article-title":"Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: antibiotics immune checkpoint inhibitors in advanced NSCLC","volume":"85","author":"Schett","year":"2020","journal-title":"Cancer Chemother. Pharm."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104767_bib82","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/annonc\/mdy453","article-title":"Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials","volume":"29","author":"Sen","year":"2018","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104767_bib83","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/gutjnl-2020-323426","article-title":"GG induces cGAS\/STING- dependent type I interferon and improves response to immune checkpoint blockade","volume":"71","author":"Si","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib84","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104767_bib85","doi-asserted-by":"crossref","unstructured":"Silva, C.A.C., Fidelle, M., Almonte, A.A., Derosa, L. & Zitvogel, L. (2024) Gut Microbiota-Related Biomarkers in Immuno-Oncology. Annu Rev Pharmacol Toxicol.","DOI":"10.1146\/annurev-pharmtox-061124-102218"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104767_bib86","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/s41591-022-01965-2","article-title":"Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome","volume":"28","author":"Simpson","year":"2022","journal-title":"Nat. Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104767_bib87","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41571-023-00803-9","article-title":"Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors","volume":"20","author":"Simpson","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6264","key":"10.1016\/j.critrevonc.2025.104767_bib88","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.104767_bib89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.critrevonc.2019.07.011","article-title":"Targeting PD-1 in cancer: Biological insights with a focus on breast cancer","volume":"142","author":"Solinas","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104767_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100811","article-title":"Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?","volume":"13","author":"Solinas","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104767_bib91","doi-asserted-by":"crossref","unstructured":"Song, Y., Peng, Y., Qin, C., Jiang, S., Lin, J., Lai, S., Wu, J., Ding, M., Du, Y., Yu, L. & Xu, T. (2024) Antibiotic use attenuates response to immune checkpoint blockade in urothelial carcinoma via inhibiting CD74-MIF\/COPA: revealing cross-talk between anti-bacterial immunity and anti-tumor immunity through a tumor marker prognostic study. Int J Surg.","DOI":"10.1097\/JS9.0000000000001901"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104767_bib92","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/s41396-023-01483-0","article-title":"Potential effects of gut microbiota on host cancers: focus on immunity, DNA damage, cellular pathways, and anticancer therapy","volume":"17","author":"Sun","year":"2023","journal-title":"ISME J."},{"issue":"7741","key":"10.1016\/j.critrevonc.2025.104767_bib93","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","article-title":"A defined commensal consortium elicits CD8 T cells and anti-cancer immunity","volume":"565","author":"Tanoue","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104767_bib94","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41571-023-00785-8","article-title":"Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy","volume":"20","author":"Thomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib95","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1634\/theoncologist.2019-0160","article-title":"Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer","volume":"25","author":"Tinsley","year":"2020","journal-title":"Oncologist"},{"issue":"26","key":"10.1016\/j.critrevonc.2025.104767_bib96","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104767_bib97","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijid.2021.03.063","article-title":"Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"106","author":"Tsikala-Vafea","year":"2021","journal-title":"Int J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104767_bib98","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.it.2012.05.003","article-title":"Antibiotics, microbiota, and immune defense","volume":"33","author":"Ubeda","year":"2012","journal-title":"Trends Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104767_bib99","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.21873\/anticanres.13836","article-title":"The impact of antibiotics on prognosis of metastatic renal cell carcinoma in japanese patients treated with immune checkpoint inhibitors","volume":"39","author":"Ueda","year":"2019","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104767_bib100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"6161","key":"10.1016\/j.critrevonc.2025.104767_bib101","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1240537","article-title":"The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide","volume":"342","author":"Viaud","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.104767_bib102","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/cancers14051327","article-title":"Association between antibiotic exposure and systemic immune parameters in cancer patients receiving checkpoint inhibitor therapy","volume":"14","author":"von Itzstein","year":"2022","journal-title":"Cancers"},{"issue":"6264","key":"10.1016\/j.critrevonc.2025.104767_bib103","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib104","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12929-019-0588-8","article-title":"Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway","volume":"26","author":"Wakabayashi","year":"2019","journal-title":"J. Biomed. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104767_bib105","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cmet.2022.02.010","article-title":"The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer","volume":"34","author":"Wang","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.critrevonc.2025.104767_bib106","doi-asserted-by":"crossref","unstructured":"Wang, M., Rousseau, B., Qiu, K., Huang, G., Zhang, Y., Su, H., Le Bihan-Benjamin, C., Khati, I., Artz, O., Foote, M.B., Cheng, Y.Y., Lee, K.H., Miao, M.Z., Sun, Y., Bousquet, P.J., Hilmi, M., Dumas, E., Hamy, A.S., Reyal, F., Lin, L., Armistead, P.M., Song, W., Vargason, A., Arthur, J.C., Liu, Y., Guo, J., Zhou, X., Nguyen, J., He, Y., Ting, J.P., Anselmo, A.C. & Huang, L. (2023) Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses. Nat Biotechnol.","DOI":"10.1038\/s41587-023-01957-8"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104767_bib107","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/CMR.0000000000000656","article-title":"Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma","volume":"30","author":"Wind","year":"2020","journal-title":"Melanoma Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104767_bib108","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41571-023-00766-x","article-title":"Gut microbiota in colorectal cancer development and therapy","volume":"20","author":"Wong","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104767_bib109","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3389\/fcell.2020.00812","article-title":"MicroRNA: Another Pharmacological Avenue for Colorectal Cancer?","volume":"8","author":"Wu","year":"2020","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.critrevonc.2025.104767_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2025.111308","article-title":"UCN expresses differently in left-sided and right-sided colon cancer contributing to distinct immune microenvironment via regulating CCL23","author":"Xiong","year":"2025","journal-title":"Hum. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib111","doi-asserted-by":"crossref","first-page":"1980347","DOI":"10.1080\/19490976.2021.1980347","article-title":"promotes colorectal cancer metastasis through miR-1322\/CCL20 axis and M2 polarization","volume":"13","author":"Xu","year":"2021","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib112","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-022-01304-4","article-title":"Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104767_bib113","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/2159-8290.CD-21-0999","article-title":"Cancer induces a stress ileopathy depending on \u03b2-adrenergic receptors and promoting dysbiosis that contributes to carcinogenesis","volume":"12","author":"Yonekura","year":"2022","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104767_bib114","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2025.104767_bib115","first-page":"11","article-title":"Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104767_bib116","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-20-0304","article-title":"Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104767_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106633","article-title":"Untangling determinants of gut microbiota and tumor immunologic status through a multi-omics approach in colorectal cancer","volume":"188","author":"Zhang","year":"2023","journal-title":"Pharm. Res"},{"key":"10.1016\/j.critrevonc.2025.104767_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106777","article-title":"Research progress on the interaction between oxidative stress and platelets: another avenue for cancer","volume":"191","author":"Zhang","year":"2023","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib119","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-023-01406-7","article-title":"Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104767_bib120","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","article-title":"Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma","volume":"7","author":"Zheng","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104767_bib121","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/1759-7714.15172","article-title":"Association of antibiotic exposure with survival in patients with extensive-stage small cell lung cancer receiving immune checkpoint inhibitor therapy","volume":"15","author":"Zhong","year":"2024","journal-title":"Thorac. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104767_bib122","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrmicro.2017.44","article-title":"Anticancer effects of the microbiome and its products","volume":"15","author":"Zitvogel","year":"2017","journal-title":"Nat. Rev. Microbiol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:28:44Z","timestamp":1762352924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":122,"alternative-id":["S1040842825001556"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104767","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The interplay between gut microbiota, antibiotics, and immune checkpoint inhibitors in patients with cancer: A narrative review with biological and clinical aspects","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104767","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104767"}}